Phio Pharmaceuticals

Company Snapshot

Founded: 2011
Entity Type: Public
Employees: 6
Region: U.S.
Headquarter: Massachusetts, U.S.
Key Geographics: North America
Corporate Address: 11 Apex Drive Suite 300APMB 2006 Marlborough Massachusetts 01752 U.S. Tel. +1-(508)-767-3861 www.phiopharma.com

Company Overview

Phio Pharmaceuticals is focused on the application of RNAi therapies via Intasyl, its proprietary technology, to immuno-oncology therapeutics. It is a clinical stage pharmaceutical and biotechnology company.

Intasyl helps in the delivery of RNAi molecules directly into the cells. It is co-founded by Craig Mello, who received the Nobel Prize for his discovery of RNAi technology.

Phio Pharmaceuticals In Reports

RNAi Drug Delivery: Technologies and Global Markets

BCC Research Market Report says global nucleic acid drug delivery market should reach $2.7 billion by 2028 from $1.1 billion in 2023 at a CAGR of 20.5%.

Synthetic Biology: Global Markets

BCC Research Market Report for synthetic biology is estimated to increase from $9.5 billion in 2021 to $33.2 billion by 2026, at a compound annual growth rate of 28.4%

Synthetic Biology: Global Markets

The global synthetic biology market should grow from $5.3 billion in 2019 to $18.9 billion by 2024 with a compound annual growth rate (CAGR) of 28.8% for the period of 2019-2024.

Company's Business Segments

  • RNAi Therapies : The company develops therapeutics utilizing their INTASYL siRNA gene silencing technology, aimed at enhancing immune cells' effectiveness in fighting cancer cells.

Applications/End User Industries

  • Biotechnology
  • Pharmaceutical
  • Life Sciences
AI Sentiment